DavidQuinnMD

Genitourinary Oncology

Medical Director of the Norris Cancer Hospital; Head, section of Genitourinary Medical Oncology; Associate Professor of Medical Oncology, USC School of Medicine

Join to view full profile

Dr. Quinn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Quinn's full profile

Already have an account?

Office
1441 Eastlake Ave
Nor 3440
Los Angeles, CA 90089
Phone+1 323-865-3111

Fax+1 323-865-0061
Is this information wrong?

Summary

Dr. David Quinn is an oncologist in Los Angeles, CA and is affiliated with multiple hospitals in the area, including Keck Hospital of USC, USC Norris Comprehensive Cancer Center, and USC Norris Comprehensive Cancer Center. He received his medical degree from University of New South Wales Faculty of Medicine and has been in practice 30 years. He specializes in genitourinary oncology and is experienced in urologic oncology and general medical oncology.

Education & Training

University of New South Wales Faculty of MedicineClass of 1987

Certifications & Licensure

CA State Medical License 2004 - 2025
American Board of Radiology Therapeutic Medical Physics

Awards, Honors, & Recognition

Best Doctors for Cancer Best Doctors
Top Doctors Castle Connolly
Super Doctor SuperDoctors.com

Clinical Trials

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Start of enrollment: 2006 Aug 01
Completed
Phase 3
Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma Start of enrollment: 2004 Nov 01
Completed
Phase 2
Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. Start of enrollment: 2001 Mar 01
Completed
Phase 2
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer Start of enrollment: 2005 Apr 30
Completed
Phase 2
Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC) Start of enrollment: 2005 Aug 18
Unknown status
Phase 1, Phase 2
Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium Start of enrollment: 2006 Jun 01
Terminated
Phase 2
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Start of enrollment: 2006 Oct 23
Active, not recruiting
Phase 1, Phase 2
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Start of enrollment: 2009 Jun 01
Active, not recruiting
Phase 2
Short-Term Fasting: Impact on Toxicity Start of enrollment: 2009 Jul 09
Active, not recruiting
Not Applicable
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2009 Dec 11
Completed
Phase 1
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2009 Oct 29
Active, not recruiting
Phase 1, Phase 2
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder Start of enrollment: 2011 Jun 13
Terminated
Phase 2
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Mar 30
Completed
Phase 2
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer Start of enrollment: 2012 Aug 01
Completed
Phase 2
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer Start of enrollment: 2013 Jan 29
Active, not recruiting
Not Applicable
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Start of enrollment: 2015 Jul 13
Completed
Phase 3
Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer Start of enrollment: 2015 Nov 11
Completed
Phase 2
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Start of enrollment: 2015 Dec 01
Completed
Phase 1, Phase 2
Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma Start of enrollment: 2016 Feb 23
Completed
Phase 1
Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors Start of enrollment: 2016 Mar 09
Terminated
Phase 2
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma Start of enrollment: 2016 Jun 01
Terminated
Phase 1
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Start of enrollment: 2018 Jul 20
Active, not recruiting
Phase 2
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer Start of enrollment: 2018 Nov 21
Active, not recruiting
Phase 2
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2019 Sep 20
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S...
Mamta Parikh, Catherine Tangen, Maha H A Hussain, Shilpa Gupta, Sam Callis, Yeonjung Jo, Andrea Harzstark, Channing J Paller, Saby George, Matthew R Zibelman, Heather ...> ;European Urology Oncology. 2024 Mar 23
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III tria...
Primo N Lara Jr, Edward Mayerson, Erik Gertz, Catherine Tangen, Amir Goldkorn, Marta van Loan, Maha Hussain, Shilpa Gupta, Jingsong Zhang, Mamta Parikh, Przemyslaw Twa...> ;Prostate Cancer and Prostatic Diseases. 2024 Feb 29
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
Do-Youn Oh, Maria Alsina Maqueda, David I Quinn, Peter J O'Dwyer, Ian Chau, Sun Young Kim, Ignacio Duran, Daniel Castellano, Jordan Berlin, Begona Mellado, Stephen K W...> ;BMC Cancer. 2023 Nov 3
1 citations
Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Po...
Marc-Oliver Grimm, Mototsugu Oya, Toni K Choueiri, Manuela Schmidinger, David I Quinn, Gwenaelle Gravis-Mescam, Elena Verzoni, Alfonsus J M Van den Eertwegh, Alessandr...> ;European Urology. 2024 Jan 1
Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial.
Nicolas Sayegh, Umang Swami, Yeonjung Jo, Georges Gebrael, Benjamin Haaland, Shilpa Gupta, Melissa Plets, Maha H A Hussain, David I Quinn, Primo N Lara Jr, Ian M Thomp...> ;JAMA Network Open. 2023 Aug 1
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials.
Emmanuel S Antonarakis, Sumit K Subudhi, Christopher M Pieczonka, Lawrence I Karsh, David I Quinn, Jason M Hafron, Helen M Wilfehrt, Matthew Harmon, Nadeem A Sheikh, N...> ;Clinical Cancer Research. 2023 Jul 5
1 citations
EphrinB2: Expression of a novel potential target in renal cell carcinoma.
Chhavi Gupta, Akash Pramod Sali, Alexandra Jackovich, Binyun Ma, Sarmad Sadeghi, David Quinn, Parkash Gill, Inderbir Gill> ;Indian Journal of Urology. 2023 Jun 30
5 citations
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
H Josh Jang, Galen Hostetter, Alexander W Macfarlane, Zachary Madaj, Eric A Ross, Toshinori Hinoue, Justin R Kulchycki, Ryan S Burgos, Mahvish Tafseer, R Katherine Alp...> ;Clinical Cancer Research. 2023 Jun 1
7 citations
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
Yi-Tsung Lu, Melissa Plets, Gareth Morrison, Alexander T Cunha, Steven Y Cen, Suhn K Rhie, Kimberly D Siegmund, Siamak Daneshmand, David I Quinn, Joshua J Meeks, Seth ...> ;European Urology Oncology. 2023 Oct 1
5 citations
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with o...
Primo N Lara Jr, Edward Mayerson, Erik Gertz, Catherine Tangen, Amir Goldkorn, Marta van Loan, Maha Hussain, Shilpa Gupta, Jingsong Zhang, Mamta Parikh, Przemyslaw Twa...> ;European Urology. 2024 Feb 1
10 citations
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
James J Harding, Sarina A Piha-Paul, Ronak H Shah, Jessica J Murphy, James M Cleary, Geoffrey I Shapiro, David I Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Shere...> ;Nature Communications. 2023 Feb 6
6 citations
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma.
Sadeghi, S., Quinn, D., Dorff, T., Pal, S., Groshen, S., Tsao-Wei, D., Parikh, R., Devitt, M., Parikh, M., Jackovich, A., Ruel, N., Vogelzang, N., Burgess, E., Siddiqi...> ;Journal of Clinical Oncology. 2023 Jan 20
10 citations
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer.
Jeffrey S Damrauer, Wolfgang Beckabir, Jeff Klomp, Mi Zhou, Elizabeth R Plimack, Matthew D Galsky, Petros Grivas, Noah M Hahn, Peter H O'Donnell, Gopa Iyer, David I Qu...> ;Nature Communications. 2022 Nov 4
10 citations
Oligometastatic Prostate Cancer: Current Status and Future Challenges.
Hossein Jadvar, Andre Luis Abreu, Leslie K Ballas, David I Quinn> ;Journal of Nuclear Medicine. 2022 Nov 1
27 citations
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on/mRNA Expression.
Cora N Sternberg, Daniel P Petrylak, Joaquim Bellmunt, Hiroyuki Nishiyama, Andrea Necchi, Howard Gurney, Jae-Lyun Lee, Michiel S van der Heijden, Eli Rosenbaum, Nicola...> ;Journal of Clinical Oncology. 2023 Jan 20
92 citations
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, rand...
Thomas Powles, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Stefan N Symeonides, Jaroslav Hajek, Howard Gurney, Yen-Hwa Chang, Jae Lyun Lee, Naveed ...> ;The Lancet. Oncology. 2022 Sep 1
3 citations
Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer.
Varsha Tulpule, Gareth J Morrison, Mary Falcone, David I Quinn, Amir Goldkorn> ;Current Oncology Reports. 2022 Oct 1
16 citations
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A Climent, Daniel P Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N Sternberg, Peter H O'Donnell, Tho...> ;Clinical Cancer Research. 2022 May 13
1 citations
A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma.
Zizhen Feng, Brendan D Curti, David I Quinn, John M Strother, Zunqiu Chen, Rebecca Agnor, Tomasz M Beer, Christopher W Ryan> ;Clinical Genitourinary Cancer. 2022 Oct 1
11 citations
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibito...
Bradley McGregor, Peter H O'Donnell, Arjun Balar, Daniel Petrylak, Jonathan Rosenberg, Evan Y Yu, David I Quinn, Elisabeth I Heath, Mary Campbell, Zsolt Hepp, Caroline...> ;European Urology. 2022 May 1
13 citations
Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).
Neeraj Agarwal, Catherine M Tangen, Maha H A Hussain, Shilpa Gupta, Melissa Plets, Primo N Lara, Andrea L Harzstark, Przemyslaw W Twardowski, Channing J Paller, Dylan ...> ;Journal of Clinical Oncology. 2022 Oct 1
2 citations
Bladder cancer: from a therapeutic wilderness to so many options; a guide to practice in a changing landscape.
Anishka A D'souza, Varsha Tulpule, Peter D Zang, David I Quinn> ;Annals of Oncology. 2022 Mar 1
8 citations
Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis.
Gareth Morrison, Jonathan Buckley, Dejerianne Ostrow, Bino Varghese, Steven Y Cen, Jeffrey Werbin, Nolan Ericson, Alexander Cunha, Yi-Tsung Lu, Thaddeus George, Jeffre...> ;International Journal of Molecular Sciences. 2022 Feb 25
23 citations
Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Ex...
Anirban P Mitra, Jie Cai, Gus Miranda, Sumeet Bhanvadia, David I Quinn, Anne K Schuckman, Hooman Djaladat, Siamak Daneshmand> ;The Journal of Urology. 2022 Feb 1
Reply by Authors.
Anirban P Mitra, Jie Cai, Gus Miranda, Sumeet Bhanvadia, David I Quinn, Anne K Schuckman, Hooman Djaladat, Siamak Daneshmand> ;The Journal of Urology. 2022 Feb 1
Join now to see all

Journal Articles

Axitinib Versus Placebo as an Adjuvant Treatment for Renal Cell Carcinoma: Results from the Phase III, Randomized ATLAS Trial
V Master, D I Quinn, Annals of Oncology
Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival
Eric J Small, David I Quinn, Clinical Cancer Research
pembrolizumab
Quinn, new england, 2017

Lectures

Adjuvant axitinib dose modification in renal cell carcinoma (RCC): Analysis of the ATLAS study.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Ground Broken on New Medical FacilityMay 3rd, 2019
Intermittent Androgen Deprivation Not Equivalent to Continuous Treatment for Prostate Cancer, May Compromise SurvivalApril 5th, 2013
Prostate Cancer Study Suggests Shorter TreatmentsFebruary 12th, 2016